Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-8708
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Montefiore - Mount Vernon HospitalResidency, Internal Medicine, 2009 - 2012
Yonsei University College of MedicineClass of 1990
Certifications & Licensure
MD State Medical License 2015 - 2026
TX State Medical License 2012 - 2016
MA State Medical License 2011 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 12 citationsTherapeutic outcome of Epstein-Barr virus positive T/NK cell lymphoma in the upper aerodigestive tract.Jee Sook Hahn, Seung-Tae Lee, Yoo Hong Min, Yun Woong Ko, Woo Ick Yang
Yonsei Medical Journal. 2002-04-01 - 77 citationsCytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leuke...Yoo Hong Min, June-Won Cheong, Jiyeon Kim, Ju In Eom, Seung-Tae Lee
Cancer Research. 2004-08-01 - 11 citationsEffect of mesenchymal stem cell transplantation on the engraftment of human hematopoietic stem cells and leukemic cells in mice model.Seung Tae Lee, Hoyoung Maeng, Yong-Joon Chwae, Duk Jae Oh, Yong-Man Kim
International Journal of Hematology. 2008-02-22
Abstracts/Posters
- A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierSeung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
